US$100 million Series C investment in Biofourmis Holdings Pte. Ltd. led by SoftBank Vision Fund II
Allen & Gledhill advised SoftBank Vision Fund II, as transaction counsel, which led the US$100 million Series C investment (“Investment”) in Biofourmis Holdings Pte. Ltd., a health start-up that combines artificial intelligence-based data analytics and biosensors to monitor the progress of medical treatments.
The Investment is a significant milestone in the growth of Biofourmis which develops artificial intelligence-powered digital therapeutic solutions to enhance conventional health services.
Advising SoftBank Vision Fund II were Allen & Gledhill Partners Christian Chin, Eugene Ho and Tan Kai Liang.